Treatment and Management of Acinetobacter Pneumonia: Lessons Learned from Recent World Event

References

• Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61–e111. doi:10.1093/cid/ciw353
   PubMed Web of Science ®Google Scholar
• Munro S, Baker D. Reducing missed oral care opportunities to prevent non-ventilator associated hospital acquired pneumonia at the Department of Veterans Affairs. Appl Nurs Res. 2018;44:48–53. doi:10.1016/j.apnr.2018.09.004
   PubMed Web of Science ®Google Scholar
• Hickey SM, Giwa AO. Mechanical Ventilation. Treasure Island (FL): StatPearls Publishing; 2023.
   Google Scholar
• Antalová N, Klučka J, Říhová M, Poláčková S, Pokorná A, Štourač P. VAPprevention in pediatric patients: narrative review. Children. 2022;9(10):1540. doi:10.3390/children9101540
   PubMedGoogle Scholar
• Charles MP, Kali A, Easow JM, et al. Ventilator-associated pneumonia. Australas Med J. 2014;7(8):334–344. doi:10.4066/AMJ.2014.2105
   PubMedGoogle Scholar
• Papazian L, Klompas M, Luyt CE. VAPin adults: a narrative review. Intensive Care Med. 2020;46(5):888–906. doi:10.1007/s00134-020-05980-0
   PubMed Web of Science ®Google Scholar
• American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388–416. doi:10.1164/rccm.200405-644ST
   PubMed Web of Science ®Google Scholar
• Seguin P, Laviolle B, Dahyot-Fizelier C, et al. Effect of oropharyngeal povidone-iodine preventive oral care on VAP in severely brain-injured or cerebral hemorrhage patients: a multicenter, randomized controlled trial. Crit Care Med. 2014;42(1):1–8. doi:10.1097/CCM.0b013e3182a2770f
   PubMed Web of Science ®Google Scholar
• Herkel T, Uvizl R, Doubravska L, et al. Epidemiology of hospital-acquired pneumonia: results of a Central European multicenter, prospective, observational study compared with data from the European region. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016;160(3):448–455. doi:10.5507/bp.2016.014
   PubMed Web of Science ®Google Scholar
• Giuliano KK, Baker D, Quinn B. The epidemiology of nonventilator hospital-acquired pneumonia in the United States. Am J Infect Control. 2018;46(3):322–327. doi:10.1016/j.ajic.2017.09.005
   PubMed Web of Science ®Google Scholar
• Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370(13):1198–1208. doi:10.1056/NEJMoa1306801
   PubMed Web of Science ®Google Scholar
• Cai B, Echols R, Magee G, et al. Prevalence of carbapenem-resistant gram-negative infections in the United States predominated by Acinetobacter baumannii and Pseudomonas aeruginosa. Open Forum Infect Dis. 2017;4(3):ofx176. doi:10.1093/ofid/ofx176
   PubMedGoogle Scholar
• Zilberberg MD, Nathanson BH, Sulham K, Fan W, Shorr AF. Multidrug resistance, inappropriate empiric therapy, and hospital mortality in Acinetobacter baumannii pneumonia and sepsis. Crit Care. 2016;20(1):221. doi:10.1186/s13054-016-1392-4
   PubMed Web of Science ®Google Scholar
• Timsit JF, Esaied W, Neuville M, Bouadma L, Mourvllier B. Update on ventilator-associated pneumonia. F1000Res. 2017;6:2061. doi:10.12688/f1000research.12222.1
   PubMedGoogle Scholar
• Arayasukawat P, So-Ngern A, Reechaipichitkul W, Chumpangern W, Arunsurat I, Ratanawatkul P. Microorganisms, and clinical outcomes of early- and late-onset VAPat Srinagarind Hospital, a tertiary center in Northeastern Thailand. BMC Pulm Med. 2021;21(1):47. doi:10.1186/s12890-021-01415-8
   PubMed Web of Science ®Google Scholar
• Čiginskienė A, Dambrauskienė A, Rello J, Adukauskienė D. VAPdue to drug-resistant Acinetobacter baumannii: risk factors and mortality relation with resistance profiles, and independent predictors of in-hospital mortality. medicina. 2019;55(2):49. doi:10.3390/medicina55020
   PubMedGoogle Scholar
• Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious diseases society of America guidance on the treatment of AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections. Clin Infect Dis. 2022;74(12):2089–2114. doi:10.1093/cid/ciab1013
   PubMed Web of Science ®Google Scholar
• Drwiega EN, Rodvold KA. Penetration of Antibacterial Agents into Pulmonary Epithelial Lining Fluid: an Update. Clin Pharmacokinet. 2022;61(1):17–46. doi:10.1007/s40262-021-01061-7
   PubMed Web of Science ®Google Scholar
• Eljaaly K, Bidell MR, Gandhi RG, et al. Colistin nephrotoxicity: meta-analysis of randomized controlled trials. Open Forum Infect Dis. 2021;8(2):ofab026. doi:10.1093/ofid/ofab026
   PubMed Web of Science ®Google Scholar
• Aydemir H, Akduman D, Piskin N, et al. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect. 2013;141(6):1214–1222. doi:10.1017/S095026881200194X
   PubMed Web of Science ®Google Scholar
• Segala FV, Bavaro DF, Di Gennaro F, et al. Impact of SARS-CoV-2 Epidemic on antimicrobial resistance: a literature review. Viruses. 2021;13(11):2110. doi:10.3390/v13112110
   PubMed Web of Science ®Google Scholar
• Vincent JL, Sakr Y, Singer M, et al. Prevalence and outcomes of infection among patients in intensive care units in 2017. JAMA. 2020;323(15):1478–1487. doi:10.1001/jama.2020.2717
   PubMed Web of Science ®Google Scholar
• Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–327. doi:10.1016/S1473-3099(17)30753-3
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Nathanson BH, Sulham K, Fan W, Shorr AF. A novel algorithm to analyze epidemiology and outcomes of carbapenem resistance among patients with hospital-acquired and ventilator-associated pneumonia: a retrospective cohort study. Chest. 2019;155(6):1119–1130. doi:10.1016/j.chest.2018.12.024
   PubMed Web of Science ®Google Scholar
• Beijerinck M. Pigmenten als oxydatieproducten gevormd door bacterien. Versl Koninklijke Akad Wetensch Amsterdam. 1911;19:1092–1103.
   Google Scholar
• Brisou J, Prevot AR. Etudes de systématique bactérienne. Ann Inst Pasteur. 1954;86(6):722–728.
   PubMedGoogle Scholar
• Baumann P, Doudoroff M, Stanier RY. A study of the Moraxella group. II. Oxidative-negative species (genus Acinetobacter). J Bacteriol. 1968;95(5):1520–1541. doi:10.1128/jb.95.5.1520-1541
   PubMed Web of Science ®Google Scholar
• Bouvet PJ, Grimont PA. Taxonomy of the genus Acinetobacter with the recognition of Acinetobacter baumannii sp. nov., Acinetobacter haemolyticus sp. nov., Acinetobacter johnsonii sp. nov., and Acinetobacter junii sp. nov., and emended description of Acinetobacter calcoaceticus and Acinetobacter lwoffii. Int J Syst Bacteriol. 1986;36:228–240.
   Google Scholar
• Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21(3):538–582. doi:10.1128/CMR.00058-07
   PubMed Web of Science ®Google Scholar
• LPSN.dsmz.de; 2023. Available from: https://www.bacterio.net/genus/acinetobacter. Accessed September 10, 2023.
   Google Scholar
• Gerner-Smidt P. Ribotyping of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex. J Clin Microbiol. 1992;30(10):2680–2685. doi:10.1128/jcm.30.10.2680-2685.1992
   PubMed Web of Science ®Google Scholar
• Nemec A, Krizova L, Maixnerova M, Sedo O, Brisse S, Higgins PG. Acinetobacter seifertii sp. nov., a member of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex isolated from human clinical specimens. Int J Syst Evol Microbiol. 2015;65(Pt3):934–942. doi:10.1099/ijs.0.000043
   PubMedGoogle Scholar
• Osgaya C, Marí-Almirall M, Van Assche A, et al. Acinetobacter dijkshoorniae sp. nov., a member of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex mainly recovered from clinical samples in different countries. Int J Syst Evol Microbiol. 2016;66(10):4105–4111. doi:10.1099/ijsem.0.001318
   PubMedGoogle Scholar
• Ramirez MS, Bonomo RA, Tolmasky ME. Carbapenemases: transforming Acinetobacter baumannii into a yet more dangerous menace. Biomolecules. 2020;10(5):720. doi:10.3390/biom10050720
   PubMed Web of Science ®Google Scholar
• Visca P, Seifert H, Towner KJ. Acinetobacter infection-an emerging threat to human health. IUBMB Life. 2011;63(12):1048–1054. doi:10.1002/iub.534
   PubMed Web of Science ®Google Scholar
• Rossau R, Van Landschoot A, Gillis M, De Ley J. Taxonomy of Moraxellaceae fam. nov., a New bacterial family to accommodate the genera Moraxella, Acinetobacter, and Psychrobacter and related organisms. Int J Syst Evolut Microbiol. 1991;41:310–319. doi:10.1099/00207713-41-2-310
   Google Scholar
• Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B, Spellberg B. Clinical and pathophysiological overview of Acinetobacter Infections: a century of challenges. Clin Microbiol Rev. 2017;30(1):409–447. doi:10.1128/CMR.00058-16
   PubMed Web of Science ®Google Scholar
• Sarshar M, Behzadi P, Scribano D, Palamara AT, Ambrosi C. Acinetobacter baumannii: an ancient commensal with weapons of a pathogen. Pathogens. 2021;10(4):387. doi:10.3390/pathogens1004
   PubMed Web of Science ®Google Scholar
• Vijayakumar S, Biswas I, Veeraraghavan B. Accurate identification of clinically important Acinetobacter spp.: an update. Future Sci OA. 2019;5(6):FSO395. doi:10.2144/fsoa-2018-0127
   PubMed Web of Science ®Google Scholar
• Li Y, Yang X, Zhao W. Emerging microtechnologies and automated systems for rapid bacterial identification and antibiotic susceptibility testing. SLAS Technol. 2017;22(6):585–608. doi:10.1177/2472630317727519
   PubMed Web of Science ®Google Scholar
• Evans BA, Amyes SG. OXA β-lactamases. Clin Microbiol Rev. 2014;27(2):241–263. doi:10.1128/CMR.00117-13
   PubMed Web of Science ®Google Scholar
• Lee YT, Turton JF, Chen TL, et al. First identification of blaOXA-51-like in non-baumannii Acinetobacter spp. J Chemother. 2009;21(5):514–520. doi:10.1179/joc.2009.21.5.514
   PubMed Web of Science ®Google Scholar
• Tjernberg I, Ursing J. Clinical strains of Acinetobacter classified by DNA-DNA hybridization. APMIS. 1989;97(7):595–605. doi:10.1111/j.1699-0463.1989.tb00449.x
   PubMed Web of Science ®Google Scholar
• Misbah S, Hassan H, Yusof MY, Hanifah YA, AbuBakar S. Genomic species identification of Acinetobacter of clinical isolates by 16S rDNA sequencing. Singapore Med J. 2005;46(9):461–464.
   PubMedGoogle Scholar
• Šedo O, Nemec A, Křížová L, Kačalová M, Zdráhal Z. Improvement of MALDI-TOF MS profiling for the differentiation of species within the Acinetobacter calcoaceticus-Acinetobacter baumannii complex. Syst Appl Microbiol. 2013;36(8):572–578. doi:10.1016/j.syapm.2013.08.001
   PubMed Web of Science ®Google Scholar
• Dortet L, Potron A, Bonnin RA, et al. Rapid detection of colistin resistance in Acinetobacter baumannii using MALDI-TOF-based lipidomics on intact bacteria. Sci Rep. 2018;8(1):16910. doi:10.1038/s41598-018-35041-y
   PubMedGoogle Scholar
• Wang Q, Zhou Y, Li S, et al. Real-time fluorescence loop mediated isothermal amplification for the detection of Acinetobacter baumannii. PLoS One. 2013;8(7):e66406. doi:10.1371/journal.pone.0066406
   PubMed Web of Science ®Google Scholar
• Cheng X, Yang J, Wang M, et al. Visual and rapid detection of Acinetobacter baumannii by a multiple cross displacement amplification combined with nanoparticles-based biosensor assay. AMB Express. 2019;9(1):30. doi:10.1186/s13568-019-0754-0
   PubMedGoogle Scholar
• Doughari HJ, Ndakidemi PA, Human IS, Benade S. The ecology, biology and pathogenesis of Acinetobacter spp.: an overview. Microbes Environ. 2011;26(2):101–112. doi:10.1264/jsme2me10179
   PubMed Web of Science ®Google Scholar
• Amorim AM, Nascimento JD. Acinetobacter: an underrated foodborne pathogen? J Infect Dev Ctries. 2017;11(2):111–114. doi:10.3855/jidc.8418
   PubMed Web of Science ®Google Scholar
• Carvalheira A, Silva J, Teixeira P. Acinetobacter spp. in food and drinking water - A review. Food Microbiol. 2021;95:103675. doi:10.1016/j.fm.2020.103675
   PubMed Web of Science ®Google Scholar
• Carvalheira A, Casquete R, Silva J, Teixeira P. Prevalence and antimicrobial susceptibility of Acinetobacter spp. isolated from meat. Int J Food Microbiol. 2017;243:58–63. doi:10.1016/j.ijfoodmicro.2016.12.001
   PubMed Web of Science ®Google Scholar
• Lund BM. Provision of microbiologically safe food for vulnerable people in hospitals, care homes and in the community. Food Control. 2019;97:535–547. doi:10.1016/j.foodcont
   Google Scholar
• Rodríguez-Baño J, Cisneros JM, Fernández-Cuenca F, et al. Clinical features and epidemiology of Acinetobacter baumannii colonization and infection in Spanish hospitals. Infect Control Hosp Epidemiol. 2004;25(10):819–824. doi:10.1086/502302
   PubMed Web of Science ®Google Scholar
• Bergogne-Bérézin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev. 1996;9(2):148–165. doi:10.1128/CMR.9.2.148
   PubMed Web of Science ®Google Scholar
• Li Y, Ge H, Zhou H, et al. Impact of environmental cleaning on the colonization and infection rates of multidrug-resistant Acinetobacter baumannii in patients within the intensive care unit in a tertiary hospital. Antimicrob Resist Infect Control. 2021;10(1):4. doi:10.1186/s13756-020-00870-y
   PubMed Web of Science ®Google Scholar
• Biderman P, Bugaevsky Y, Ben-Zvi H, Bishara J. Multidrug-resistant Acinetobacter baumannii infections in lung transplant patients in the cardiothoracic intensive care unit. Clin Transplant. 2015;29(9):756–762. doi:10.1111/ctr.12575
   PubMed Web of Science ®Google Scholar
• Harding CM, Hennon SW, Feldman MF. Uncovering the mechanisms of Acinetobacter baumannii virulence. Nat Rev Microbiol. 2018;16(2):91–102. doi:10.1038/nrmicro.2017.148
   PubMed Web of Science ®Google Scholar
• Alouane T, Uwingabiye J, Lemnouer A, et al. First whole-genome sequences of two multidrug-resistant Acinetobacter baumannii Strains Isolated from a Moroccan Hospital Floor. Genome Announc. 2017;5(18):e00298–17. doi:10.1128/genomeA.00298-17
   PubMedGoogle Scholar
• Lupo A, Haenni M, Madec JY. Antimicrobial resistance in Acinetobacter spp. And Pseudomonas spp. Microbiol Spectr. 2018;6:3. doi:10.1128/microbiolspec.ARBA-0007-2017
   Web of Science ®Google Scholar
• Krol V, Hamid NS, Cunha BA. Neurosurgically related nosocomial Acinetobacter baumannii meningitis: report of two cases and literature review. J Hosp Infect. 2009;71(2):176–180. doi:10.1016/j.jhin.2008.09.018
   PubMed Web of Science ®Google Scholar
• Peacock SJ, Parkhill J, Brown NM. Changing the paradigm for hospital outbreak detection by leading with genomic surveillance of nosocomial pathogens. Microbiology. 2018;164(10):1213–1219. doi:10.1099/mic.0.000700
   PubMed Web of Science ®Google Scholar
• Joly-Guillou M-L, Brun-Buisson C. Epidemiology of Acinetobacter spp.: surveillance and management of outbreaks. In: Acinetobacter. CRC Press; 2020:28,71–100. doi:10.1201/9781003069263-4
   Google Scholar
• Antunes LC, Visca P, Towner KJ. Acinetobacter baumannii: evolution of a global pathogen. Pathog Dis. 2014;71(3):292–301. doi:10.1111/2049-632X.12125
   PubMed Web of Science ®Google Scholar
• Ma C, McClean S. Mapping Global Prevalence of Acinetobacter baumannii and Recent Vaccine Development to Tackle It. Vaccines. 2021;9(6):570. doi:10.3390/vaccines9060570
   Web of Science ®Google Scholar
• Gautam D, Dolma KG, Khandelwal B, et al. Acinetobacter baumannii: an overview of emerging multidrug-resistant pathogen. Med J Malaysia. 2022;77(3):357–370.
   PubMedGoogle Scholar
• Colquhoun JM, Rather PN. Insights Into Mechanisms of Biofilm Formation in Acinetobacter baumannii and Implications for Uropathogenesis. Front Cell Infect Microbiol. 2020;10:253. doi:10.3389/fcimb.2020.00253
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Gutiérrez-Pizarraya A, Díaz-Martín A, et al. Acinetobacter baumannii in critically ill patients: molecular epidemiology, clinical features and predictors of mortality. Enferm Infecc Microbiol Clin. 2016;34(9):551–558. doi:10.1016/j.eimc.2015.11.018
   PubMed Web of Science ®Google Scholar
• López-Hernández S, Alarcón T, López-Brea M. Carbapenem resistance mediated by beta-lactamases in clinical isolates of Acinetobacter baumannii in Spain. Eur J Clin Microbiol Infect Dis. 1998;17(4):282–285. doi:10.1007/BF01699988
   PubMed Web of Science ®Google Scholar
• Husni RN, Goldstein LS, Arroliga AC, et al. Risk factors for an outbreak of multi-drug-resistant Acinetobacter nosocomial pneumonia among intubated patients. Chest. 1999;115(5):1378–1382. doi:10.1378/chest.115.5.1378
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Ortiz-Leyba C, Fernández-Hinojosa E, et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med. 2005;31(5):649–655. doi:10.1007/s00134-005-2598-0
   PubMed Web of Science ®Google Scholar
• Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest. 2002;122(1):262–268. doi:10.1378/chest.122.1.262
   PubMed Web of Science ®Google Scholar
• Sader HS, Castanheira M, Mendes RE, Flamm RK. Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015-17). J Antimicrob Chemother. 2018;73(11):3053–3059. doi:10.1093/jac/dky279
   PubMed Web of Science ®Google Scholar
• Saleem M, Syed Khaja AS, Hossain A, et al. Molecular characterization and antibiogram of Acinetobacter baumannii clinical isolates recovered from the patients with ventilator-associated pneumonia. Healthcare. 2022;10(11):2210. doi:10.3390/healthcare10112210
   Web of Science ®Google Scholar
• Royer S, Faria AL, Seki LM, et al. Spread of multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa clones in patients with VAPin an adult intensive care unit at a university hospital. Braz J Infect Dis. 2015;19(4):350–357. doi:10.1016/j.bjid.2015.03.009
   PubMed Web of Science ®Google Scholar
• Koulenti D, Lisboa T, Brun-Buisson C, et al. Spectrum of practice in the diagnosis of nosocomial pneumonia in patients requiring mechanical ventilation in European intensive care units. Crit Care Med. 2009;37(8):2360–2368. doi:10.1097/CCM.0b013e3181a037ac
   PubMed Web of Science ®Google Scholar
• Bassetti M, Righi E, Vena A, Graziano E, Russo A, Peghin M. Risk stratification and treatment of ICU-acquired pneumonia caused by multidrug- resistant/extensively drug-resistant/pandrug-resistant bacteria. Curr Opin Crit Care. 2018;24(5):385–393. doi:10.1097/MCC.0000000000000534
   PubMed Web of Science ®Google Scholar
• Behera B, Mahapatra A, Kunjan Pillai JS, et al. Infection-Related ventilator-associated complication and possible VAPamong mechanically ventilated patients of adult medical and surgical intensive care units. J Lab Physicians. 2022;15(1):45–47. doi:10.1055/s-0042-1750076
   PubMedGoogle Scholar
• He Q, Wang W, Zhu S, et al. The epidemiology and clinical outcomes of ventilator-associated events among 20,769 mechanically ventilated patients at intensive care units: an observational study. Crit Care. 2021;25(1):44. doi:10.1186/s13054-021-03484-x
   PubMed Web of Science ®Google Scholar
• Kanafani ZA, Zahreddine N, Tayyar R, et al. Multi-drug resistant Acinetobacter species: a seven-year experience from a tertiary care center in Lebanon. Antimicrob Resist Infect Control. 2018;7:9. doi:10.1186/s13756-017-0297-6
   PubMed Web of Science ®Google Scholar
• Hoang Quoc C. Carbapenemase genes and multidrug resistance of Acinetobacter baumannii: a cross sectional study of patients with pneumonia in southern Vietnam. Antibiotics. 2019;8(3):148. doi:10.3390/antibiotics8030148
   Web of Science ®Google Scholar
• Gedefie A, Demsis W, Ashagrie M, et al. Acinetobacter baumannii Biofilm formation and its role in disease pathogenesis: a review. Infect Drug Resist. 2021;14:3711–3719. doi:10.2147/IDR.S332051
   PubMed Web of Science ®Google Scholar
• Howard A, O’Donoghue M, Feeney A, Sleator RD. Acinetobacter baumannii: an emerging opportunistic pathogen. Virulence. 2012;3(3):243–250. doi:10.4161/viru.19700
   PubMed Web of Science ®Google Scholar
• Bouadma L, Sonneville R, Garrouste-Orgeas M, et al. Ventilator-associated events: prevalence, outcome, and relationship with ventilator-associated pneumonia. Crit Care Med. 2015;43(9):1798–1806. doi:10.1097/CCM.0000000000001091
   PubMed Web of Science ®Google Scholar
• Nowak J, Zander E, Stefanik D, et al. High incidence of pandrug-resistant Acinetobacter baumannii isolates collected from patients with VAPin Greece, Italy and Spain as part of the MagicBullet clinical trial. J Antimicrob Chemother. 2017;72(12):3277–3282. doi:10.1093/jac/dkx322
   PubMed Web of Science ®Google Scholar
• Almomani BA, McCullough A, Gharaibeh R, Samrah S. Incidence, and predictors of 14-day mortality in multidrug-resistant Acinetobacter baumannii in ventilator-associated pneumonia. J Infect Dev Ctries. 2015;9(12):1323–1330. doi:10.3855/jidc.6812
   PubMed Web of Science ®Google Scholar
• Ziółkowski G, Pawłowska I, Krawczyk L, Wojkowska-Mach J. Antibiotic consumption versus the prevalence of multidrug-resistant Acinetobacter baumannii and Clostridium difficile infections at an ICU from 2014-2015. J Infect Public Health. 2018;11(5):626–630. doi:10.1016/j.jiph.2018.02.003
   PubMed Web of Science ®Google Scholar
• Özgür ES, Horasan ES, Karaca K, Ersöz G, Naycı Atış S, Kaya A. VAPdue to extensive drug-resistant Acinetobacter baumannii: risk factors, clinical features, and outcomes. Am J Infect Control. 2014;42(2):206–208. doi:10.1016/j.ajic.2013.09.003
   PubMed Web of Science ®Google Scholar
• Ju M, Hou D, Chen S, et al. Risk factors for mortality in ICU patients with Acinetobacter baumannii ventilator-associated pneumonia: impact of bacterial cytotoxicity. J Thorac Dis. 2018;10(5):2608–2617. doi:10.21037/jtd.2018.04.86
   PubMed Web of Science ®Google Scholar
• Pei Y, Huang Y, Pan X, et al. Nomogram for predicting 90-day mortality in patients with Acinetobacter baumannii-caused hospital-acquired and VAPin the respiratory intensive care unit. J Int Med Res. 2023;51(3):3000605231161481. doi:10.1177/03000605231161481
   Web of Science ®Google Scholar
• Lemos EV, de la Hoz FP, Einarson TR, et al. Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis. Clin Microbiol Infect. 2014;20(5):416–423. doi:10.1111/1469-0691.12363
   PubMed Web of Science ®Google Scholar
• Mohd Sazlly Lim S. The global prevalence of multidrug-resistance among Acinetobacter baumannii causing hospital-acquired and VAPand its associated mortality: a systematic review and meta-analysis. J Infect. 2019;79(6):593–600. doi:10.1016/j.jinf.2019.09.012
   PubMed Web of Science ®Google Scholar
• Du X, Xu X, Yao J, et al. Predictors of mortality in patients infected with carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis. Am J Infect Control. 2019;47(9):1140–1145. doi:10.1016/j.ajic.2019.03.003
   PubMed Web of Science ®Google Scholar
• Adukauskiene D, Ciginskiene A, Adukauskaite A, Koulenti D, Rello J. Clinical features and outcomes of monobacterial and polybacterial episodes of VAPdue to multidrug-resistant Acinetobacter baumannii. Antibiotics. 2022;11(7):892. doi:10.3390/antibiotics11070892
   Google Scholar
• Dexter C, Murray GL, Paulsen IT, Peleg AY. Community-acquired Acinetobacter baumannii: clinical characteristics, epidemiology and pathogenesis. Expert Rev Anti Infect Ther. 2015;13(5):567–573. doi:10.1586/14787210.2015.1025055
   PubMed Web of Science ®Google Scholar
• Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol. 2007;5(12):939–951. doi:10.1038/nrmicro1789
   PubMed Web of Science ®Google Scholar
• Villegas MV, Hartstein AI. Acinetobacter outbreaks, 1977-2000. Infect Control Hosp Epidemiol. 2003;24(4):284–295. doi:10.1086/502205
   PubMed Web of Science ®Google Scholar
• Monterrubio-Villar J, González-Velasco C, Valdezate-Ramos S, Córdoba-López A, Villalón-Panzano P, Saéz-Nieto JA. Outbreak of multiresistant Acinetobacter baumannii in a polyvalent intensive care unit: clinical, epidemiological analysis and PFGE-printing evolution. Eur J Clin Microbiol Infect Dis. 2009;28(10):1281–1284. doi:10.1007/s10096-009-0777-6
   PubMed Web of Science ®Google Scholar
• Araújo lima AV, da Silva SM. Occurrence and diversity of intra- and interhospital drug-resistant and biofilm-forming Acinetobacter baumannii and Pseudomonas aeruginosa. Microb Drug Resist. 2020;26(7):802–814. doi:10.1089/mdr.2019.0214
   PubMed Web of Science ®Google Scholar
• Schulte B, Goerke C, Weyrich P, et al. Clonal spread of meropenem-resistant Acinetobacter baumannii strains in hospitals in the Mediterranean region and transmission to South-west Germany. J Hosp Infect. 2005;61(4):356–357. doi:10.1016/j.jhin.2005.05.009
   PubMed Web of Science ®Google Scholar
• Meumann EM, Anstey NM, Currie BJ, et al. Genomic epidemiology of severe community-onset Acinetobacter baumannii infection. Microb Genom. 2019;5(3):e000258. doi:10.1099/mgen.0.000258
   PubMed Web of Science ®Google Scholar
• Jia H, Sun Q, Ruan Z, Xie X. Characterization of a small plasmid carrying the carbapenem resistance gene blaOXA-72 from community-acquired Acinetobacter baumannii sequence type 880 in China. Infect Drug Resist. 2019;12:1545–1553. doi:10.2147/IDR.S202803
   PubMed Web of Science ®Google Scholar
• Sharma AK, Dhasmana N, Dubey N, et al. Bacterial virulence factors: secreted for survival. Indian J Microbiol. 2017;57(1):1–10. doi:10.1007/s12088-016-0625-1
   PubMed Web of Science ®Google Scholar
• Kumar S, Anwer R, Azzi A. Virulence potential and treatment options of multidrug-resistant (MDR) Acinetobacter baumannii. Microorganisms. 2021;9(10):2104. doi:10.3390/microorganisms9102104
   PubMed Web of Science ®Google Scholar
• Lee CR, Lee JH, Park M, et al. Biology of Acinetobacter baumannii: pathogenesis, antibiotic resistance mechanisms, and prospective treatment options. Front Cell Infect Microbiol. 2017;13(7):55. doi:10.3389/fcimb.2017.00055
   Google Scholar
• Ayoub Moubareck C, Hammoudi Halat D. Insights into Acinetobacter baumannii: a review of microbiological, virulence, and resistance traits in a threatening nosocomial pathogen. Antibiotics. 2020;9(3):119. doi:10.3390/antibiotics9030119
   Web of Science ®Google Scholar
• McConnell MJ, Actis L, Pachón J. Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models. FEMS Microbiol Rev. 2013;37(2):130–155. doi:10.1111/j.1574-6976.2012.00344.x
   PubMed Web of Science ®Google Scholar
• Smith SG, Mahon V, Lambert MA, Fagan RP. A molecular Swiss army knife: ompA structure, function and expression. FEMS Microbiol Lett. 2007;273(1):1–11. doi:10.1111/j.1574-6968.2007.00778.x
   PubMed Web of Science ®Google Scholar
• Smani Y, Dominguez-Herrera J, Pachón J. Association of the outer membrane protein Omp33 with fitness and virulence of Acinetobacter baumannii. J Infect Dis. 2013;208(10):1561–1570. doi:10.1093/infdis/jit386
   PubMed Web of Science ®Google Scholar
• Rumbo C, Tomás M, Fernández Moreira E, et al. The Acinetobacter baumannii Omp33-36 porin is a virulence factor that induces apoptosis and modulates autophagy in human cells. Infect Immun. 2014;82(11):4666–4680. doi:10.1128/IAI.02034-14
   PubMed Web of Science ®Google Scholar
• Zhu LJ, Chen XY, Hou PF. Mutation of CarO participates in drug resistance in imipenem-resistant Acinetobacter baumannii. J Clin Lab Anal. 2019;33(8):e22976. doi:10.1002/jcla.22976
   PubMed Web of Science ®Google Scholar
• Sato Y, Unno Y, Kawakami S, Ubagai T, Ono Y. Virulence characteristics of Acinetobacter baumannii clinical isolates vary with the expression levels of omps. J Med Microbiol. 2017;66(2):203–212. doi:10.1099/jmm.0.000394
   PubMed Web of Science ®Google Scholar
• Gil-Marqués ML, Pachón J, Smani Y. iTRAQ-Based quantitative proteomic analysis of Acinetobacter baumannii under hypoxia and normoxia reveals the role of OmpW as a virulence factor. Microbiol Spectr. 2022;10(2):e0232821. doi:10.1128/spectrum.02328-21
   PubMed Web of Science ®Google Scholar
• Uppalapati SR, Sett A, Pathania R. The Outer membrane proteins OmpA, CarO, and OprD of Acinetobacter baumannii confer a two-pronged defense in facilitating its success as a potent human pathogen. Front Microbiol. 2020;11:589234. doi:10.3389/fmicb.2020.589234
   PubMed Web of Science ®Google Scholar
• Kulp A, Kuehn MJ. Biological functions and biogenesis of secreted bacterial outer membrane vesicles. Annu Rev Microbiol. 2010;64:163–184. doi:10.1146/annurev.micro.091208.073413
   PubMed Web of Science ®Google Scholar
• Jun SH, Lee JH, Kim BR, et al. Acinetobacter baumannii outer membrane vesicles elicit a potent innate immune response via membrane proteins. PLoS One. 2013;8(8):e71751. doi:10.1371/journal.pone.0071751
   PubMed Web of Science ®Google Scholar
• Nho JS, Jun SH, Oh MH, et al. Acinetobacter nosocomialis secretes outer membrane vesicles that induce epithelial cell death and host inflammatory responses. Microb Pathog. 2015;81:39–45. doi:10.1016/j.micpath.2015.03.012
   PubMed Web of Science ®Google Scholar
• Rumbo C, Fernández-Moreira E, Merino M, et al. Horizontal transfer of the OXA-24 carbapenemase gene via outer membrane vesicles: a new mechanism of dissemination of carbapenem resistance genes in Acinetobacter baumannii. Antimicrob Agents Chemother. 2011;55(7):3084–3090. doi:10.1128/AAC.00929-10
   PubMed Web of Science ®Google Scholar
• Huang W, Yao Y, Long Q, et al. Immunization against multidrug-resistant Acinetobacter baumannii effectively protects mice in both pneumonia and sepsis models. PLoS One. 2014;9(6):e100727. doi:10.1371/journal.pone.0100727
   PubMed Web of Science ®Google Scholar
• Dehbanipour R, Ghalavand Z. Acinetobacter baumannii: pathogenesis, virulence factors, novel therapeutic options and mechanisms of resistance to antimicrobial agents with emphasis on tigecycline. J Clin Pharm Ther. 2022;47(11):1875–1884. doi:10.1111/jcpt.13787
   PubMed Web of Science ®Google Scholar
• Knapp S, Wieland CW, Florquin S, et al. Differential roles of CD14 and toll-like receptors 4 and 2 in murine Acinetobacter pneumonia. Am J Respir Crit Care Med. 2006;173(1):122–129. doi:10.1164/rccm.200505-730OC
   PubMed Web of Science ®Google Scholar
• Rossi E, Longo F, Barbagallo M, et al. Glucose availability enhances lipopolysaccharide production and immunogenicity in the opportunistic pathogen Acinetobacter baumannii. Future Microbiol. 2016;11(3):335–349. doi:10.2217/fmb.15.153
   PubMed Web of Science ®Google Scholar
• Haseley SR, Pantophlet R, Brade L, Holst O, Brade H. Structural and serological characterisation of the O-antigenic polysaccharide of the lipopolysaccharide from Acinetobacter junii strain 65. Eur J Biochem. 1997;245(2):477–481. doi:10.1111/j.1432-1033.1997.t01-1-00477.x
   PubMedGoogle Scholar
• Geisinger E, Isberg RR. Antibiotic modulation of capsular exopolysaccharide and virulence in Acinetobacter baumannii. PLoS Pathog. 2015;11(2):e1004691. doi:10.1371/journal.ppat.1004691
   PubMed Web of Science ®Google Scholar
• van der Meer-Janssen YP, van Galen J, Batenburg JJ, Helms JB. Lipids in host-pathogen interactions: pathogens exploit the complexity of the host cell lipidome. Prog Lipid Res. 2010;49(1):1–26. doi:10.1016/j.plipres.2009.07.003
   PubMed Web of Science ®Google Scholar
• Camarena L, Bruno V, Euskirchen G, Poggio S, Snyder M. Molecular mechanisms of ethanol-induced pathogenesis revealed by RNA-sequencing. PLoS Pathog. 2010;6(4):e1000834. doi:10.1371/journal.ppat.1000834
   PubMed Web of Science ®Google Scholar
• Flores-Díaz M, Monturiol-Gross L, Naylor C, Alape-Girón A, Flieger A. Bacterial sphingomyelinases and phospholipases as virulence factors. Microbiol Mol Biol Rev. 2016;80(3):597–628. doi:10.1128/MMBR.00082-15
   PubMed Web of Science ®Google Scholar
• Stahl J, Bergmann H, Göttig S, Ebersberger I, Averhoff B. Acinetobacter baumannii virulence is mediated by the concerted action of three phospholipases D. PLoS One. 2015;10(9):e0138360. doi:10.1371/journal.pone.0138360
   PubMed Web of Science ®Google Scholar
• Tomaras AP, Dorsey CW, Edelmann RE, Actis LA. Attachment to and biofilm formation on abiotic surfaces by Acinetobacter baumannii: involvement of a novel chaperone-usher pili assembly system. Microbiology. 2003;149(Pt 12):3473–3484. doi:10.1099/mic.0.26541-0
   PubMed Web of Science ®Google Scholar
• Özarslan TO, Sirmatel F, Karabörk SO, Düzcü SE, Astarci HM. Acinetobacter baumannii pneumonia increases surfactant proteins SP-A, SP-B, and SP-D levels, while decreasing SP-C level in bronchoalveolar lavage in rats. Microbes Infect. 2023;25:105064. doi:10.1016/j.micinf.2022.105064
   Web of Science ®Google Scholar
• Waack U, Warnock M, Yee A, et al. cpaa is a glycan-specific adamalysin-like protease secreted by Acinetobacter baumannii that inactivates coagulation factor XII. mBio. 2018;9(6):e01606–18. doi:10.1128/mBio.01606-18
   PubMed Web of Science ®Google Scholar
• Tilley D, Law R, Warren S, Samis JA, Kumar A. CpaA a novel protease from Acinetobacter baumannii clinical isolates deregulates blood coagulation. FEMS Microbiol Lett. 2014;356(1):53–61. doi:10.1111/1574-6968.12496
   PubMed Web of Science ®Google Scholar
• Law SKK, Tan HS. The role of quorum sensing, biofilm formation, and iron acquisition as key virulence mechanisms in Acinetobacter baumannii and the corresponding anti-virulence strategies. Microbiol Res. 2022;260:127032. doi:10.1016/j.micres.2022.127032
   PubMedGoogle Scholar
• Antunes LC, Imperi F, Towner KJ, Visca P. Genome-assisted identification of putative iron-utilization genes in Acinetobacter baumannii and their distribution among a genotypically diverse collection of clinical isolates. Res Microbiol. 2011;162(3):279–284. doi:10.1016/j.resmic.2010.10.010
   PubMed Web of Science ®Google Scholar
• Miethke M, Marahiel MA. Siderophore-based iron acquisition and pathogen control. Microbiol Mol Biol Rev. 2007;71(3):413–451. doi:10.1128/MMBR.00012-07
   PubMed Web of Science ®Google Scholar
• Ferreira D, Seca AML. Targeting human pathogenic bacteria by siderophores: a proteomics review. J Proteomics. 2016;145:153–166. doi:10.1016/j.jprot.2016.04.006
   PubMed Web of Science ®Google Scholar
• Kim M, Kim DY, Song WY, et al. distinctive roles of two acinetobactin isomers in challenging host nutritional immunity. mBio. 2021;12(5):e0224821. doi:10.1128/mBio.02248-21
   PubMed Web of Science ®Google Scholar
• Penwell WF, Arivett BA, Actis LA. The Acinetobacter baumannii entA gene located outside the acinetobactin cluster is critical for siderophore production, iron acquisition and virulence. PLoS One. 2012;7(5):e36493. doi:10.1371/journal.pone.0036493
   PubMed Web of Science ®Google Scholar
• Conde-Pérez K, Vázquez-Ucha JC, Álvarez-Fraga L, et al. In-depth analysis of the role of the acinetobactin cluster in the virulence of Acinetobacter baumannii. Front Microbiol. 2021;12:752070. doi:10.3389/fmicb.2021.752070
   PubMed Web of Science ®Google Scholar
• Nairn BL, Lonergan ZR, Wang J, et al. The Response of Acinetobacter baumannii to Zinc Starvation. Cell Host Microbe. 2016;19(6):826–836. doi:10.1016/j.chom.2016.05.007
   PubMed Web of Science ®Google Scholar
• Repizo GD. Prevalence of Acinetobacter baumannii strains expressing the Type 6 secretion system in patients with bacteremia. Virulence. 2017;8(7):1099–1101. doi:10.1080/21505594.2017.1346768
   PubMed Web of Science ®Google Scholar
• Weber BS, Hennon SW, Wright MS, et al. Genetic dissection of the type vi secretion system in Acinetobacter and identification of a novel peptidoglycan hydrolase, TagX, required for its biogenesis. mBio. 2016;7(5):e01253–16. doi:10.1128/mBio.01253-16
   PubMed Web of Science ®Google Scholar
• Johnson TL, Waack U, Smith S, Mobley H, Sandkvist M. Acinetobacter baumannii Is dependent on the type ii secretion system and its substrate lipa for lipid utilization and in vivo fitness. J Bacteriol. 2015;198(4):711–719. doi:10.1128/JB.00622-15
   PubMed Web of Science ®Google Scholar
• Russo TA, Manohar A, Beanan JM, et al. The response regulator bfmr is a potential drug target for Acinetobacter baumannii. mSphere. 2016;1(3):e00082–16. doi:10.1128/mSphere.00082-16
   PubMed Web of Science ®Google Scholar
• Yang CH, Su PW, Moi SH, Chuang LY. Biofilm formation in Acinetobacter baumannii: genotype-phenotype correlation. Molecules. 2019;24(10):1849. doi:10.3390/molecules24101849
   PubMed Web of Science ®Google Scholar
• Flemming HC, van Hullebusch ED, Neu TR, et al. The biofilm matrix: multitasking in a shared space. Nat Rev Microbiol. 2023;21(2):70–86. doi:10.1038/s41579-022-00791-0
   PubMed Web of Science ®Google Scholar
• Greene C, Wu J, Rickard AH, Xi C. Evaluation of the ability of Acinetobacter baumannii to form biofilms on six different biomedical relevant surfaces. Lett Appl Microbiol. 2016t;63(4):233–239. doi:10.1111/lam.12627
   PubMed Web of Science ®Google Scholar
• Loehfelm TW, Luke NR, Campagnari AA. Identification and characterization of an Acinetobacter baumannii biofilm-associated protein. J Bacteriol. 2008;190(3):1036–1044. doi:10.1128/JB.01416-07
   PubMed Web of Science ®Google Scholar
• Choi AH, Slamti L, Avci FY, Pier GB, Maira-Litrán T. The pgaABCD locus of Acinetobacter baumannii encodes the production of poly-beta-1-6-N-acetylglucosamine, which is critical for biofilm formation. J Bacteriol. 2009;191(19):5953–5963. doi:10.1128/JB.00647-09
   PubMed Web of Science ®Google Scholar
• Treter J, Macedo AJ. Catheters: a suitable surface for biofilm formation. Sci Against Microbial Pathogens. 2011;2(3):835–842.
   Google Scholar
• Li H, Song C, Liu D, Ai Q, Yu J. Molecular analysis of biofilms on the surface of neonatal endotracheal tubes based on 16S rRNA PCR-DGGE and species-specific PCR. Int J Clin Exp Med. 2015;8(7):11075–11084.
   PubMed Web of Science ®Google Scholar
• Bardes JM, Waters C, Motlagh H, Wilson A. The Prevalence of oral flora in the biofilm microbiota of the endotracheal tube. Am Surg. 2016;82(5):403–406.
   PubMed Web of Science ®Google Scholar
• Ferreira Tde O, Koto RY. Microbial investigation of biofilms recovered from endotracheal tubes using sonication in intensive care unit pediatric patients. Braz J Infect Dis. 2016t;20(5):468–475. doi:10.1016/j.bjid.2016.07.003
   PubMed Web of Science ®Google Scholar
• Vandecandelaere I, Matthijs N, Nelis HJ, Depuydt P, Coenye T. The presence of antibiotic-resistant nosocomial pathogens in endotracheal tube biofilms and corresponding surveillance cultures. Pathog Dis. 2013;69(2):142–148. doi:10.1111/2049-632X.12100
   PubMed Web of Science ®Google Scholar
• Perkins SD, Woeltje KF, Angenent LT. Endotracheal tube biofilm inoculation of oral flora and subsequent colonization of opportunistic pathogens. Int J Med Microbiol. 2010;300(7):503–511. doi:10.1016/j.ijmm.2010.02.005
   PubMed Web of Science ®Google Scholar
• Coppadoro A, Bellani G. Non-Pharmacological Interventions to Prevent Ventilator-Associated Pneumonia: a Literature Review. Respir Care. 2019;64(12):1586–1595. doi:10.4187/respcare.07127
   PubMed Web of Science ®Google Scholar
• Sottile FD, Marrie TJ, Prough DS, et al. Nosocomial pulmonary infection: possible etiologic significance of bacterial adhesion to endotracheal tubes. Crit Care Med. 1986;14(4):265–270.
   PubMed Web of Science ®Google Scholar
• Jarrett WA, Ribes J, Manaligod JM. (2002) Biofilm formation on tracheostomy tubes. Ear Nose Throat J. 2002;81(9):659–661. doi:10.1177/014556130208100915
   PubMedGoogle Scholar
• M’hamedi I, Hassaine H, Bellifa S, Lachachi M, Terki IK, Djeribi R. Biofilm formation by Acinetobacter baumannii isolated from medical devices at the intensive care unit of the University Hospital of Tlemcen (Algeria). African J Microbio Res. 2014;8(3):270–276. doi:10.5897/AJMR2013.6288
   Google Scholar
• Dargahi Z, Hamad AA, Sheikh AF, et al. The biofilm formation and antibiotic resistance of bacterial profile from endotracheal tube of patients admitted to intensive care unit in southwest of Iran. PLoS One. 2022;17(11):e0277329. doi:10.1371/journal.pone.0277329
   PubMed Web of Science ®Google Scholar
• Raveendra N, Rathnakara SH, Haswani N, Subramaniam V. Bacterial biofilms on tracheostomy tubes. Indian J Otolaryngol Head Neck Surg. 2022;74:4995–4999. doi:10.1007/s12070-021-02598-6
   PubMed Web of Science ®Google Scholar
• Diaconu O, Siriopol I, Poloșanu LI, Grigoraș I. Endotracheal tube biofilm and its impact on the pathogenesis of ventilator-associated pneumonia. J Crit Care Med. 2018;4(2):50–55. doi:10.2478/jccm-2018-0011
   Web of Science ®Google Scholar
• Cairns S, Thomas JG, Hooper SJ, et al. Molecular analysis of microbial communities in endotracheal tube biofilms. PLoS One. 2011;6(3):e14759. doi:10.1371/journal.pone.0014759
   PubMed Web of Science ®Google Scholar
• Baidya S, Sharma S, Mishra SK, Kattel HP, Parajuli K, Sherchand JB. Biofilm formation by pathogens causing VAPat intensive care units in a tertiary care hospital: an armor for refuge. Biomed Res Int. 2021;2021:8817700. doi:10.1155/2021/8817700
   PubMed Web of Science ®Google Scholar
• Khoshnood S, Sadeghifard N, Mahdian N, et al. Antimicrobial resistance and biofilm formation capacity among Acinetobacter baumannii strains isolated from patients with burns and ventilator-associated pneumonia. J Clin Lab Anal. 2023;37(1):e24814. doi:10.1002/jcla.24814
   PubMed Web of Science ®Google Scholar
• Whiteley M, Diggle SP, Greenberg EP. Progress in and promise of bacterial quorum sensing research. Nature. 2017;551(7680):313–320. doi:10.1038/nature24624
   PubMed Web of Science ®Google Scholar
• Rémy B, Mion S, Plener L, Elias M, Chabrière E, Daudé D. Interference in bacterial quorum sensing: a biopharmaceutical perspective. Front Pharmacol. 2018;9:203. doi:10.3389/fphar.2018.00203
   PubMed Web of Science ®Google Scholar
• Saipriya K, Swathi CH, Ratnakar KS, Sritharan V. Quorum-sensing system in Acinetobacter baumannii: a potential target for new drug development. J Appl Microbiol. 2020;128(1):15–27. doi:10.1111/jam.14330
   PubMed Web of Science ®Google Scholar
• Xiong L, Yi F, Yu Q, et al. Transcriptomic analysis reveals the regulatory role of quorum sensing in the Acinetobacter baumannii ATCC 19606 via RNA-seq. BMC Microbiol. 2022;22(1):198. doi:10.1186/s12866-022-02612-z
   PubMed Web of Science ®Google Scholar
• Sun X, Ni Z, Tang J, Ding Y, Wang X, Li F. The abaI/abaR quorum sensing system effects on pathogenicity in Acinetobacter baumannii. Front Microbiol. 2021;12:679241. doi:10.3389/fmicb.2021.679241
   PubMedGoogle Scholar
• Abraham WR. Going beyond the Control of Quorum-Sensing to Combat Biofilm Infections. Antibiotics. 2016;5(1):3. doi:10.3390/antibiotics5010003
   Google Scholar
• Yoshimura J, Kinoshita T, Yamakawa K, et al. Impact of Gram stain results on initial treatment selection in patients with ventilator-associated pneumonia: a retrospective analysis of two treatment algorithms. Crit Care. 2017;21(1):156. doi:10.1186/s13054-017-1747-5
   PubMedGoogle Scholar
• Khan R, Al-Dorzi HM, Tamim HM, et al. The impact of onset time on the isolated pathogens and outcomes in ventilator associated pneumonia. J Infect Public Health. 2016;9(2):161–171. doi:10.1016/j.jiph.2015.09.002
   PubMed Web of Science ®Google Scholar
• Craven DE, Hudcova J, Lei Y. Diagnosis of ventilator-associated respiratory infections (VARI): microbiologic clues for tracheobronchitis (VAT) and pneumonia (VAP). Clin Chest Med. 2011;32(3):547–557. doi:10.1016/j.ccm.2011.06.001
   PubMed Web of Science ®Google Scholar
• Nair GB, Niederman MS. Ventilator-associated pneumonia: present understanding and ongoing debates. Intensive Care Med. 2015;41(1):34–48. doi:10.1007/s00134-014-3564-5
   PubMed Web of Science ®Google Scholar
• Dudeck MA, Horan TC, Peterson KD, et al. National Healthcare Safety Network (NHSN) Report, data summary for 2010, device-associated module. Am J Infect Control. 2011;39(10):798–816. doi:10.1016/j.ajic.2011.10.001
   PubMed Web of Science ®Google Scholar
• Metersky ML, Wang Y, Klompas M, Eckenrode S, Bakullari A, Eldridge N. trend in VAPrates between 2005 and 2013. JAMA. 2016;316(22):2427–2429. doi:10.1001/jama.2016.16226
   PubMed Web of Science ®Google Scholar
• Kalanuria AA, Ziai W, Mirski M. VAPin the ICU. Crit Care. 2014;18(2):208. doi:10.1186/cc13775
   PubMed Web of Science ®Google Scholar
• ANVISA. Agência Nacional de Vigilância Sanitária. 2013. Critérios diagnósticos de infecção relacionada à assistência à saúde.4-150.
   Google Scholar
• Prates CG, Martins AF, Superti SV, et al. Risk factors for 30-day mortality in patients with carbapenem-resistant Acinetobacter baumannii during an outbreak in an intensive care unit. Epidemiol Infect. 2011;139(3):411–418. doi:10.1017/S0950268810001238
   PubMed Web of Science ®Google Scholar
• Zahar JR, Timsit JF, Garrouste-Orgeas M, et al. Outcomes in severe sepsis and patients with septic shock: pathogen species and infection sites are not associated with mortality. Crit Care Med. 2011;39(8):1886–1895. doi:10.1097/CCM.0b013e31821b827c
   PubMed Web of Science ®Google Scholar
• Tabah A, Koulenti D, Laupland K, et al. Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Med. 2012;38(12):1930–1945. doi:10.1007/s00134-012-2695-9
   PubMed Web of Science ®Google Scholar
• Sarda C, Fazal F, Rello J. Management of VAP(VAP) caused by resistant gram-negative bacteria: which is the best strategy to treat? Expert Rev Respir Med. 2019;13(8):787–798. doi:10.1080/17476348.2019.1632195
   PubMed Web of Science ®Google Scholar
• Reignier J, Darmon M, Sonneville R, et al. Impact of early nutrition and feeding route on outcomes of mechanically ventilated patients with shock: a post hoc marginal structural model study. Intensive Care Med. 2015;41(5):875–886. doi:10.1007/s00134-015-3730-4
   PubMed Web of Science ®Google Scholar
• Fitch ZW, Whitman GJ. Incidence, risk, and prevention of VAPin adult cardiac surgical patients: a systematic review. J Card Surg. 2014;29(2):196–203. doi:10.1111/jocs.12260
   PubMed Web of Science ®Google Scholar
• Schwebel C. Safety of intrahospital transport in ventilated critically ill patients: a multicenter cohort study. Crit Care Med. 2013;41(8):1919–1928. doi:10.1097/CCM.0b013e31828a3bbd
   PubMed Web of Science ®Google Scholar
• Bornstain C, Azoulay E, De Lassence A, et al. Sedation, sucralfate, and antibiotic use are potential means for protection against early-onset ventilator-associated pneumonia. Clin Infect Dis. 2004;38(10):1401–1408. doi:10.1086/386321
   PubMed Web of Science ®Google Scholar
• Kadri SS, Adjemian J, Lai YL, et al. Difficult-to-treat resistance in gram-negative bacteremia at 173 us hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents. Clin Infect Dis. 2018;67(12):1803–1814. doi:10.1093/cid/ciy378
   PubMed Web of Science ®Google Scholar
• Vazquez Guillamet C, Kollef MH. Acinetobacter pneumonia: improving outcomes with early identification and appropriate therapy. Clin Infect Dis. 2018;67(9):1455–1462. doi:10.1093/cid/ciy375
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii VAP(VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis. 2003;36(9):1111–1118. doi:10.1086/374337
   PubMed Web of Science ®Google Scholar
• Superti SV, Martins Dde S, Caierão J, Soares Fda S, Prochnow T, Zavascki AP. Indications of carbapenem resistance evolution through heteroresistance as an intermediate stage in Acinetobacter baumannii after carbapenem administration. Rev Inst Med Trop Sao Paulo. 2009;51(2):111–113. doi:10.1590/s0036-46652009000200010
   PubMed Web of Science ®Google Scholar
• Fishbain J, Peleg AY. Treatment of Acinetobacter infections. Clin Infect Dis. 2010;51(1):79–84. doi:10.1086/653120
   PubMed Web of Science ®Google Scholar
• Levin AS, Levy CE, Manrique AE, Medeiros EA, Costa SF. Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. Int J Antimicrob Agents. 2003;21(1):58–62. doi:10.1016/s0924-8579(02)00276-5
   PubMed Web of Science ®Google Scholar
• Wood GC, Hanes SD, Croce MA, Fabian TC, Boucher BA. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia. Clin Infect Dis. 2002;34(11):1425–1430. doi:10.1086/340055
   PubMed Web of Science ®Google Scholar
• Chu H, Zhao L, Wang M, Liu Y, Gui T, Zhang J. Sulbactam-based therapy for Acinetobacter baumannii infection: a systematic review and meta-analysis. Braz J Infect Dis. 2013;17(4):389–394. doi:10.1016/j.bjid.2012.10.029
   PubMed Web of Science ®Google Scholar
• Penwell WF, Shapiro AB, Giacobbe RA, et al. Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii. Antimicrob Agents Chemother. 2015;59(3):1680–1689. doi:10.1128/AAC.04808-14
   PubMed Web of Science ®Google Scholar
• Ritchie DJ, Garavaglia-Wilson A. A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections. Clin Infect Dis. 2014;59 Suppl 6:S374–80. doi:10.1093/cid/ciu613
   PubMed Web of Science ®Google Scholar
• Lee YT, Tsao SM, Hsueh PR. Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections. Eur J Clin Microbiol Infect Dis. 2013;32(9):1211–1220. doi:10.1007/s10096-013-1870-4
   PubMed Web of Science ®Google Scholar
• Freire AT, Melnyk V, Kim MJ, et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis. 2010;68(2):140–151. doi:10.1016/j.diagmicrobio.2010.05.012
   PubMed Web of Science ®Google Scholar
• Rando E, Cutuli SL, Sangiorgi F, et al. Cefiderocol-containing regimens for the treatment of carbapenem-resistant A. baumannii ventilator-associated pneumonia: a propensity-weighted cohort study. JAC Antimicrob Resist. 2023;5(4):dlad085. doi:10.1093/jacamr/dlad085
   PubMedGoogle Scholar
• Corcione S, De Benedetto I, Pinna SM, et al. Cefiderocol use in Gram negative infections with limited therapeutic options: is combination therapy the key? J Infect Public Health. 2022;15(9):975–979. doi:10.1016/j.jiph.2022.07.006
   PubMed Web of Science ®Google Scholar
• Alp E, Eren E, Elay G, Cevahir F, Esmaoğlu A, Rello J. Efficacy of loading dose of colistin in Acinetobacter baumannii ventilator-associated pneumonia. Infez Med. 2017;25(4):311–319.
   PubMedGoogle Scholar
• Wang J, Niu H, Wang R, Cai Y. Safety and efficacy of colistin alone or in combination in adults with Acinetobacter baumannii infection: a systematic review and meta-analysis. Int J Antimicrob Agents. 2019;53(4):383–400. doi:10.1016/j.ijantimicag.2018.10.020
   PubMed Web of Science ®Google Scholar
• Khawcharoenporn T, Pruetpongpun N, Tiamsak P, Rutchanawech S, Mundy LM, Apisarnthanarak A. Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia. Int J Antimicrob Agents. 2014;43(4):378–382. doi:10.1016/j.ijantimicag.2014.01.016
   PubMed Web of Science ®Google Scholar
• Biagi M, Butler D, Tan X, Qasmieh S, Wenzler E. A breath of fresh air in the fog of antimicrobial resistance: inhaled polymyxins for gram-negative pneumonia. Antibiotics. 2019;8(1):27. doi:10.3390/antibiotics8010027
   Google Scholar
• Moghaddam O, Niakan Lahiji M, Talebi-Taher M, Mahmoodiyeh B. effect of inhaled colistin on the treatment of VAPdue to multi-drug resistant Acinetobacter. Tanaffos. 2019;18(1):66–73.
   PubMedGoogle Scholar
• Valachis A, Samonis G, Kofteridis DP. The role of aerosolized colistin in the treatment of ventilator-associated pneumonia: a systematic review and metaanalysis. Crit Care Med. 2015;43(3):527–533. doi:10.1097/CCM.0000000000000771
   PubMed Web of Science ®Google Scholar
• Solé-Lleonart C, Rouby JJ, Blot S, et al. Nebulization of Antiinfective Agents in Invasively Mechanically Ventilated Adults: a Systematic Review and Meta-analysis. Anesthesiology. 2017;126(5):890–908. doi:10.1097/ALN.0000000000001570
   PubMed Web of Science ®Google Scholar
• Kisil OV, Efimenko TA, Gabrielyan NI, et al. Development of antimicrobial therapy methods to overcome the antibiotic resistance of Acinetobacter baumannii. Acta Naturae. 2020;12(3):34–45. doi:10.32607/actanaturae.10955
   PubMed Web of Science ®Google Scholar
• Comeau AM, Hatfull GF, Krisch HM, et al. Exploring the prokaryotic virosphere. Res Microbiol. 2008;159(5):306–313. doi:10.1016/j.resmic.2008.05.001
   PubMed Web of Science ®Google Scholar
• Bagińska N, Pichlak A, Górski A, et al. Specific and selective bacteriophages in the fight against multidrug-resistant Acinetobacter baumannii. Virol Sin. 2019;34(4):347–357. doi:10.1007/s12250-019-00125-0
   PubMed Web of Science ®Google Scholar
• Jung CJ, Liao YD, Hsu CC, et al. Identification of potential therapeutic antimicrobial peptides against Acinetobacter baumannii in a mouse model of pneumonia. Sci Rep. 2021;11(1):7318. doi:10.1038/s41598-021-86844-5
   PubMed Web of Science ®Google Scholar
• Losasso C, Belluco S, Cibin V, et al. Antibacterial activity of silver nanoparticles: sensitivity of different Salmonella serovars. Front Microbiol. 2014;26(5):227. doi:10.3389/fmicb.2014.00227
   Google Scholar
• Intorasoot A, Chornchoem P, Sookkhee S, et al. Bactericidal activity of herbal volatile oil extracts against multidrug-resistant Acinetobacter baumannii. J Intercult Ethnopharmacol. 2017;6(2):218–222. doi:10.5455/jice.20170411091159
   PubMedGoogle Scholar
• Meng L, Wang C, Li J, Zhang J. Early vs late tracheostomy in critically ill patients: a systematic review and meta-analysis. Clin Respir J. 2016;10(6):684–692. doi:10.1111/crj.12286
   PubMed Web of Science ®Google Scholar
• Klompas M, Branson R, Eichenwald EC, et al. Strategies to prevent VAPin acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014;35:S133–54. doi:10.1017/s0899823x00193894
   PubMedGoogle Scholar
• Rello J, Lode H, Cornaglia G, Masterton R, VAP Care Bundle Contributors. A European care bundle for prevention of ventilator-associated pneumonia. Intensive Care Med. 2010;36(5):773–780. doi:10.1007/s00134-010-1841-5
   PubMed Web of Science ®Google Scholar
• Speck K, Rawat N, Weiner NC, Tujuba HG, Farley D, Berenholtz S. A systematic approach for developing a VAPprevention bundle. Am J Infect Control. 2016;44(6):652–656. doi:10.1016/j.ajic.2015.12.020
   PubMed Web of Science ®Google Scholar
• Roquilly A, Marret E, Abraham E, Asehnoune K. Pneumonia prevention to decrease mortality in intensive care unit: a systematic review and meta-analysis. Clin Infect Dis. 2015;60(1):64–75. doi:10.1093/cid/ciu740
   PubMed Web of Science ®Google Scholar
• de Smet AM, Kluytmans JA, Cooper BS, et al. Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J Med. 2009;360(1):20–31. doi:10.1056/NEJMoa0800394
   PubMed Web of Science ®Google Scholar
• Klompas M. Oropharyngeal Decontamination with Antiseptics to Prevent Ventilator-Associated Pneumonia: rethinking the Benefits of Chlorhexidine. Semin Respir Crit Care Med. 2017;38(3):381–390. doi:10.1055/s-0037-1602584
   PubMed Web of Science ®Google Scholar
• LPSN.dsmz.de; 2023. Available from:https://classic.clinicaltrials.gov/ct2/show/. Accessed September 10, 2023.
   Google Scholar
• Aloush SM. Does educating nurses with VAPprevention guidelines improve their compliance? Am J Infect Control. 2017;45(9):969–973. doi:10.1016/j.ajic.2017.04.009
   PubMed Web of Science ®Google Scholar
• Jansson M, Ala-Kokko T, Ylipalosaari P, Syrjälä H, Kyngäs H. Critical care nurses’ knowledge of, adherence to and barriers towards evidence-based guidelines for the prevention of ventilator-associated pneumonia--a survey study. Intensive Crit Care Nurs. 2013;29(4):216–227. doi:10.1016/j.iccn.2013.02.006
   PubMed Web of Science ®Google Scholar
• Madhuvu A, Endacott R, Plummer V, Morphet J. Nurses’ knowledge, experience and self-reported adherence to evidence-based guidelines for prevention of ventilator-associated events: a national online survey. Intensive Crit Care Nurs. 2020;59:102827. doi:10.1016/j.iccn.2020.102827
   PubMed Web of Science ®Google Scholar
• Madhuvu A, Endacott R, Plummer V, Morphet J. Healthcare professional views on barriers to implementation of evidence-based practice in prevention of ventilator-associated events: a qualitative descriptive study. Intensive Crit Care Nurs. 2022;68:103133. doi:10.1016/j.iccn.2021.103133
   PubMed Web of Science ®Google Scholar
• Jam R, Mesquida J, Hernández Ó, et al. Nursing workload and compliance with non-pharmacological measures to prevent ventilator-associated pneumonia: a multicentre study. Nurs Crit Care. 2018;23(6):291–298. doi:10.1111/nicc.12380
   PubMed Web of Science ®Google Scholar
• Bouadma L, Mourvillier B, Deiler V, et al. Changes in knowledge, beliefs, and perceptions throughout a multifaceted behavioral program aimed at preventing ventilator-associated pneumonia. Intensive Care Med. 2010;36(8):1341–1347. doi:10.1007/s00134-010-1890-9
   PubMed Web of Science ®Google Scholar
• Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): a Review. JAMA. 2020;324(8):782–793. doi:10.1001/jama.2020.12839
   PubMed Web of Science ®Google Scholar
• Maes M, Higginson E, Pereira-Dias J, et al. VAPin critically ill patients with COVID-19. Crit Care. 2021;25(1):25. doi:10.1186/s13054-021-03460-5
   PubMedGoogle Scholar
• François B, Laterre PF, Luyt CE, Chastre J. The challenge of VAPdiagnosis in COVID-19 patients. Crit Care. 2020;24(1):289. doi:10.1186/s13054-020-03013-2
   PubMedGoogle Scholar
• Jain S, Khanna P, Sarkar S. Comparative evaluation of VAPin critically ill COVID- 19 and patients infected with other Corona viruses: a systematic review and meta-analysis. Monaldi Arch Chest Dis. 2021;92:2. doi:10.4081/monaldi.2021.1610
   Google Scholar
• Ippolito M, Misseri G, Catalisano G, et al. VAPin patients with covid-19: a systematic review and meta-analysis. Antibiotics. 2021;10(5):545. doi:10.3390/antibiotics10050545
   Google Scholar
• Gamberini L, Tonetti T, Spadaro S, et al. Factors influencing liberation from mechanical ventilation in coronavirus disease 2019: multicenter observational study in fifteen Italian ICUs. J Intensive Care. 2020;8:80. doi:10.1186/s40560-020-00499-4
   PubMed Web of Science ®Google Scholar
• Nseir S, Martin-Loeches I, Povoa P, et al. Relationship between VAPand mortality in COVID-19 patients: a planned ancillary analysis of the coVAPid cohort. Crit Care. 2021;25(1):177. doi:10.1186/s13054-021-03588-4
   PubMed Web of Science ®Google Scholar
• Meawed TE, Ahmed SM, Mowafy SMS, Samir GM, Anis RH. Bacterial and fungal ventilator associated pneumonia in critically ill COVID-19 patients during the second wave. J Infect Public Health. 2021;14(10):1375–1380. doi:10.1016/j.jiph.2021.08.003
   PubMed Web of Science ®Google Scholar
• Pascale R, Bussini L, Gaibani P, et al. Carbapenem-resistant bacteria in an intensive care unit during the coronavirus disease 2019 (COVID-19) pandemic: a multicenter before-and-after cross-sectional study. Infect Control Hosp Epidemiol. 2022;43(4):461–466. doi:10.1017/ice.2021.144
   PubMed Web of Science ®Google Scholar
• Gottesman T, Fedorowsky R, Yerushalmi R, Lellouche J, Nutman A. An outbreak of carbapenem-resistant Acinetobacter baumannii in a COVID-19 dedicated hospital. Infect Prev Pract. 2021;3(1):100113. doi:10.1016/j.infpip.2021.100113
   PubMedGoogle Scholar
• Shinohara DR. Outbreak of endemic carbapenem-resistant Acinetobacter baumannii in a coronavirus disease 2019 (COVID-19)-specific intensive care unit. Infect Control Hosp Epidemiol. 2022;43(6):815–817. doi:10.1017/ice.2021.98
   PubMed Web of Science ®Google Scholar
• Rouyer M, Strazzulla A, Youbong T, et al. VAPin COVID-19 Patients: a Retrospective Cohort Study. Antibiotics. 2021;10(8):988. doi:10.3390/antibiotics10080988
   Google Scholar
• Zand F, Vakili H, Asmarian N, et al. Unintended impact of COVID-19 pandemic on the rate of catheter related nosocomial infections and incidence of multiple drug resistance pathogens in three intensive care units not allocated to COVID-19 patients in a large teaching hospital. BMC Infect Dis. 2023;23(1):11. doi:10.1186/s12879-022-07962-7
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Battaglini D, Enrile EM, et al. Incidence and prognosis of VAPin critically ill patients with COVID-19: a multicenter study. J Clin Med. 2021;10(4):555. doi:10.3390/jcm10040555
   PubMed Web of Science ®Google Scholar
• Gregorczyk-Maga I, Pałka A, Fiema M, et al. Correction: impact of tooth brushing on oral bacteriota and health care-associated infections among ventilated COVID-19 patients: an intervention study. Antimicrob Resist Infect Control. 2023;12(1):51. doi:10.1186/s13756-023-01256-6
   PubMed Web of Science ®Google Scholar
• Puzniak L, Bauer KA, Yu KC, et al. Effect of inadequate empiric antibacterial therapy on hospital outcomes in SARS-CoV-2-positive and -negative us patients with a positive bacterial culture: a multicenter evaluation from march to November 2020. Open Forum Infect Dis. 2021;8(6):ofab232. doi:10.1093/ofid/ofab232
   PubMed Web of Science ®Google Scholar
• Jeffreys S, Chambers JP, Yu JJ, Hung CY, Forsthuber T, Arulanandam BP. Insights into Acinetobacter baumannii protective immunity. Front Immunol. 2022;13:1070424. doi:10.3389/fimmu.2022.1070424
   PubMed Web of Science ®Google Scholar
• Cox MJ, Loman N, Bogaert D, O’Grady J. Co-infections: potentially lethal and unexplored in COVID-19. Lancet Microbe. 2020;1(1):e11. doi:10.1016/S2666-5247(20)30009-4
   PubMedGoogle Scholar
• Cureño-Díaz MA, Durán-Manuel EM, Cruz-Cruz C, et al. Impact of the modification of a cleaning and disinfection method of mechanical ventilators of COVID-19 patients and ventilator-associated pneumonia: one year of experience. Am J Infect Control. 2021;49(12):1474–1480. doi:10.1016/j.ajic.2021.09.012
   PubMed Web of Science ®Google Scholar
• Perez S, Innes GK, Walters MS, et al. Increase in hospital-acquired carbapenem-resistant Acinetobacter baumannii infection and colonization in an acute care hospital during a surge in COVID-19 admissions - New Jersey, February-July 2020. MMWR Morb Mortal Wkly Rep. 2020;69(48):1827–1831. doi:10.15585/mmwr.mm6948e1
   PubMed Web of Science ®Google Scholar
• Vijay S, Bansal N, Rao BK, et al. Secondary infections in hospitalized COVID-19 patients: Indian experience. Infect Drug Resist. 2021;14:1893–1903. doi:10.2147/IDR.S299774
   PubMed Web of Science ®Google Scholar
• Loyola-Cruz MÁ, Durán-Manuel EM, Cruz-Cruz C, et al. ESKAPE bacteria characterization reveals the presence of Acinetobacter baumannii and Pseudomonas aeruginosa outbreaks in COVID-19/VAP patients. Am J Infect Control. 2023;51(7):729–737. doi:10.1016/j.ajic.2022.08.012
   PubMedGoogle Scholar
• Ukuhor HO. The interrelationships between antimicrobial resistance, COVID-19, past, and future pandemics. J Infect Public Health. 2021;14(1):53–60. doi:10.1016/j.jiph.2020.10.018
   PubMed Web of Science ®Google Scholar